NCT03827317 is a NA clinical trial of [18F]GE-226 in Breast Cancer, sponsored by Imperial College London.

Who is sponsoring NCT03827317?

NCT03827317 is sponsored by Imperial College London.

What drugs are being tested in NCT03827317?

Interventions in NCT03827317: [18F]GE-226.

What condition does NCT03827317 study?

NCT03827317 studies Breast Cancer.

Is NCT03827317 still recruiting?

NCT03827317 is currently recruiting now. Last updated 26 August 2024.

Last reviewed 2024-08-26 · How we verify

NCT03827317

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer

Recruiting now NA Last updated 26 August 2024

What this trial tests

NA trial testing [18F]GE-226 in Breast Cancer in 24 participants. Currently enrolling.

Timeline

8 March 2019

Primary endpoint
31 March 2026

31 December 2026

Quick facts

Lead sponsor	Imperial College London
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	24
Start date	8 March 2019
Primary completion	31 March 2026
Estimated completion	31 December 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

[18F]GE-226

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Imperial College London

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This mechanistic study will be the first study to assess the efficacy of \[18F\]GE-226 to target HER2 expression in patients with metastatic breast cancer. The study will establish the pharmacokinetics of \[18F\]GE-226 and the optimum time-point for performing static scans in this patient population.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.
Altunay B, Morgenroth A, Beheshti M, Vogg A, et al · · 2021 · cited 74× · PMID 33179151 · DOI 10.1007/s00259-020-05094-1
Application of PET Tracers in Molecular Imaging for Breast Cancer.
Boers J, de Vries EFJ, Glaudemans AWJM, Hospers GAP, et al · · 2020 · cited 25× · PMID 32627087 · DOI 10.1007/s11912-020-00940-9
Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.
Ge S, Li J, Yu Y, Chen Z, et al · · 2021 · cited 17× · PMID 34770887 · DOI 10.3390/molecules26216482
Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications.
Altena R, Tzortzakakis A, Af Burén S, Tran TA, et al · · 2023 · cited 9× · PMID 37195374 · DOI 10.1186/s13550-023-00995-2
Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment.
Nsereko Y, Armstrong A, Coburn F, Al Musaimi O. · · 2025 · cited 2× · PMID 40725089 · DOI 10.3390/ijms26146815
ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications.
Linguanti F, Abenavoli EM, Calabretta R, Berti V, et al · · 2023 · cited 2× · PMID 38136430 · DOI 10.3390/cancers15245886

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03827317 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 26 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03827317.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing